Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 May;29(1):17–22. doi: 10.1007/BF00199911

The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells

John Leslie Collins 1,✉, Ming-Shian Kao 1
PMCID: PMC11038550  PMID: 2706637

Abstract

It has been proposed that a component of the antitumor potential of the chemotherapeutic agent, cisplatin, resides in the host's ability to respond to cisplatintreated tumor cells. Here we report that tumor cells that are normally resistant to lysis mediated by naturally occurring cytotoxic cells showed an increased sensitivity to lysis mediated by murine spleen cells or human peripheral blood monocytes and lymphocytes when cisplatin was added at the beginning of the lytic assay. This was shown for the lysis of both murine and human tumor cells. The pretreatment of tumor cells, but not effector cells with cisplatin caused an increase in lysis in the presence of murine spleen cells or human peripheral blood leukocytes, indicating that the effect of cisplatin is to reduce resistance to lysis by these effector cells. The lysis of tumor cells by naturally occurring cytotoxic cells was blocked by antibodies specific for tumor necrosis factor. In addition, the ability of cisplatin to increase lysis was seen with cells that are sensitive to natural cytotoxic cells, but not with cells that are sensitive to natural killer cells. These results suggest that the effector cells that mediate the lysis of these tumor cells in the presence of cisplatin are likely to be natural cytotoxic cells. The ability of cisplatin to increase the lysis of tumor cells by naturally occurring cytotoxic cells indicates that these cells may be a host defense mechanism that contributes to the anticancer potential of cisplatin.

Keywords: Tumor Cell, Natural Killer, Natural Killer Cell, Effector Cell, Human Peripheral Blood

References

  • 1.Alberts DS, Chen HSB. Cloning of human tumor cells. New York: Alan Liss Inc; 1980. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay; p. 3518. [PubMed] [Google Scholar]
  • 2.Bagasra O, Currao L, DeSouza LR, Oosterhuis JW, Damjanov Immune response of mice exposed to cis-diamminedichloroplatinum. Cancer Immunol Immunother. 1985;19:142. doi: 10.1007/BF00199723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chary KK, Higby DJ, Henderson ES, Swinerton KD. Phase I study of high dose cis-dichlorodiammineplatinum (II) with forced diuresis. Cancer Treat Rep. 1977;61:367. [PubMed] [Google Scholar]
  • 4.Collins JL, Patek PQ, Cohn M. Tumorigenicity and lysis by natural killers. J Exp Med. 1981;153:89. doi: 10.1084/jem.153.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Collins JL, Patek PQ, Cohn M. In vivo surveillance of tumorigenic cells transformed in vitro. Nature. 1982;299:169. doi: 10.1038/299169a0. [DOI] [PubMed] [Google Scholar]
  • 6.Collins JL, Patek PQ, Lin Y, Cohn M. The cloned cell line L10A2. J expresses natural cytotoxic activity. Cell Immunol. 1983;103:191. doi: 10.1016/0008-8749(86)90080-8. [DOI] [PubMed] [Google Scholar]
  • 7.Collins JL, Lin Y, Patek PQ. Dissociation of contactnoninhibition in vitro and tumorigenicity in vivo. Cell Biol Int Rep. 1986;10:789. doi: 10.1016/0309-1651(86)90149-9. [DOI] [PubMed] [Google Scholar]
  • 8.Collins JL, Kao M-S, Patek PQ. Humans express natural cytotoxic (NC) cell activity that is similar to murine NC cell activity. J Immunol. 1987;138:4180. [PubMed] [Google Scholar]
  • 9.Epstein R, Cohn M. T-cell inhibition of humoral responsiveness. I. Experimental evidence for restriction by K- and/or D-end of the H-2 complex. Cell Immunol. 1978;39:110. doi: 10.1016/0008-8749(78)90088-6. [DOI] [PubMed] [Google Scholar]
  • 10.Gottlieb JA, Drewink OB. Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep. 1975;59:621. [PubMed] [Google Scholar]
  • 11.Higby DJ, Wallace HJ, Albert DJ, Holland JF. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer. 1974;33:1219. doi: 10.1002/1097-0142(197405)33:5<1219::aid-cncr2820330505>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  • 12.Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King JJ (1975) Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 59:647 [PubMed]
  • 13.Kiessling R, Klein E, Wigzell H. ‘Natural’ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Clin Immunol. 1975;5:112. doi: 10.1002/eji.1830050208. [DOI] [PubMed] [Google Scholar]
  • 14.Kleinerman ES, Zwelling LA. Effects of cisplatin, bleomycin and DTIC on immune function in vitro and in vivo. Clin Immunol Allergy. 1984;4:279. [Google Scholar]
  • 15.Kociba RJ, Sleight SD, Rosenberg B. Inhibition of Dunning ascitic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875) Cancer Chemother Rep. 1970;54:325. [PubMed] [Google Scholar]
  • 16.Lin Y, Collins JL, Patek PQ, Cohn M. An analysis of the sensitivity of somatic cell hybrids to natural killer and natural cytotoxic cell-mediated lysis. J Immunol. 1983;131:1154. [PubMed] [Google Scholar]
  • 17.Lozzio CB, Lozzio BB. Human myelogenous leukemia cell line with positive Philadelphia chromosome. Blood. 1975;45:321. [PubMed] [Google Scholar]
  • 18.Patek PQ, Collins JL, Cohn M. Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis. Nature. 1978;276:510. doi: 10.1038/276510a0. [DOI] [PubMed] [Google Scholar]
  • 19.Patek PQ, Collins JL, Cohn M. Evidence that cytotoxic T-cells and natural cytotoxic cells use different lytic mechanisms to lyse the same targets. Eur J Immunol. 1983;13:433. doi: 10.1002/eji.1830130516. [DOI] [PubMed] [Google Scholar]
  • 20.Patek PQ, Lin Y, Collins JL, Cohn M. In vivo or in vitro selection for resistance to natural cytotoxic cell lysis selects for variants with increased tumorigenicity. J Immunol. 1986;136:741. [PubMed] [Google Scholar]
  • 21.Patek PQ, Lin Y, Collins JL. Natural cytotoxic cells and tumor necrosis factor activate similar lytic mechanisms. J Immunol. 1987;138:1641. [PubMed] [Google Scholar]
  • 22.Rosenberg B. Advances in antimicrobial and antineoplastic chemotherapy, vol II. Baltimore: University Park Press; 1980. Enhanced antigenicity as a possible mode of action of platinum antitumor drugs; p. 101. [Google Scholar]
  • 23.Rosenberg B. Cisplatin: current status and new developments. New York: Academic Press; 1980. Cisplatin: its history and possible mechanism of action; p. 9. [Google Scholar]
  • 24.Rosenberg B, VanCamp L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 1970;30:1799. [PubMed] [Google Scholar]
  • 25.Rosenberg B, VanCamp L, Trosko J, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature. 1969;222:385. doi: 10.1038/222385a0. [DOI] [PubMed] [Google Scholar]
  • 26.Schlaefli E, Ehrke MJ, Mihich E. The effects of dichloro-trans-dihydroxy-bis-isopropylamine-platinum IV on the primary cell mediated cytotoxic response. Immunopharmacology. 1983;6:107. doi: 10.1016/0162-3109(83)90004-8. [DOI] [PubMed] [Google Scholar]
  • 27.Scovell WM, O'Connor T. -[(NH3)2Interaction of aquated cisPtII] with nucleic acid constituents. J Am Chem Soc. 1977;99:120. doi: 10.1021/ja00443a023. [DOI] [PubMed] [Google Scholar]
  • 28.Stutman O, Cuttito MJ. Normal levels of natural cytotoxic cells against solid tumors in NK deficient beige mice. Nature. 1981;290:254. doi: 10.1038/290254a0. [DOI] [PubMed] [Google Scholar]
  • 29.Talley RW. Chemotherapy of a mouse reticulum cell sarcoma with platinum salts. Proc Am Assoc Cancer Res. 1970;11:78. [Google Scholar]
  • 30.Timonen T, Ortaldo JR, Herberman RB. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med. 1981;153:569. doi: 10.1084/jem.153.3.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Vonka V, Kutinova L, Drobnik J, Brauerova J. Increase of Epstein-Bar-virus-positive cells in EB3 cultures after treatment with cis-dichlorodiammine-platinum (II) J Natl Cancer Inst. 1972;48:1277. [PubMed] [Google Scholar]
  • 32.Welsch CW. Growth inhibition of rat mammary carcinoma induced by cis-platinum diamminodichloride II. J Natl Cancer Inst. 1971;47:1071. [PubMed] [Google Scholar]
  • 33.Wright KC, Carrasco CH, Wallace S, Stephens LC. Treatment of the rabbit V-2 carcinoma with intralesional cisplatin. Chemother. 1985;31:60. doi: 10.1159/000238315. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES